EGFR and non-small cell lung carcinoma: A subsequent phase III study (KEYNOTE-189) of patients with metastatic EGFR/ALK wild-type nonsquamous NSCLC has shown that, compared with pemetrexed and platinum-based chemotherapy alone, first-line pembrolizumab plus chemotherapy conferred better OS (median, 22.0 vs. 10.7 months; HR, 0.56; 95% CI, 0.45–0.70), 3-year OS rate (31.3 vs. 17.4%) and PFS (median, 9.0 vs. 4.9 months; HR, 0.48; 95% CI, 0.40–0.58); ORR (48.0% vs. 19.4%) was also extended by 28.6% in patients who received combination therapy (33).